Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · Real-Time Price · USD

80.28

+3.39 (4.41%)

At close: Nov 13, 2026, 4:00 PM EST

81.22

+0.94 (1.17%)

After-hours: Nov 13, 2026, 7:30 PM EST

Tarsus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	136.53	183.64	94.82	224.95	71.66	171.33
Short-Term Investments	173.08	233.63	196.56	2.5	145.37	0.48
Cash & Short-Term Investments	309.61	417.27	291.38	227.44	217.03	171.82
Cash Growth	-22.95%	43.21%	28.11%	4.80%	26.31%	2.19%
Accounts Receivable	100.44	85.06	46.76	16.62	-	-
Other Receivables	1.67	2.05	1.3	1.09	3.58	0.09
Receivables	102.11	87.11	48.06	17.71	3.58	0.09
Inventory	5.16	4.37	2.62	3.11	-	-
Prepaid Expenses	28.54	13.47	14.65	7.87	4.77	4.05
Restricted Cash	-	0.56	-	-	-	-
Total Current Assets	445.42	522.78	356.71	256.13	225.38	175.95
Property, Plant & Equipment	31.11	21.75	2.87	3.35	1.53	1.83
Long-Term Investments	6.68	3.87	3	0.86	0.48	0.66
Other Intangible Assets	16.65	7.37	8.33	3.87	-	-
Other Long-Term Assets	5.64	6.4	6.09	1.29	0.48	0.46
Total Assets	505.5	562.16	376.99	265.49	227.86	178.91

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	34.69	16.39	9.42	17.77	5.5	2.86
Accrued Expenses	108.31	26.88	19.14	13.9	9.21	7.26
Current Portion of Leases	0.77	-	0.61	0.4	0.72	0.61
Current Income Taxes Payable	5.67	1.81	-	-	-	0.06
Current Unearned Revenue	-	-	-	-	-	0.7
Other Current Liabilities	77.68	90.62	51.44	4.87	-	-
Total Current Liabilities	227.11	135.7	80.61	36.94	15.43	11.48
Long-Term Debt	72.94	72.44	71.85	29.82	19.43	-
Long-Term Leases	15.73	10.6	-	-	-	0.59
Other Long-Term Liabilities	85.69	-	-	1.75	0.1	0.11
Total Liabilities	401.47	218.73	152.46	68.5	34.96	12.18

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	1,225	769.67	584.56	441.64	301.73	213.4
Retained Earnings	-1,120	-426.63	-360.21	-244.66	-108.76	-46.67
Comprehensive Income & Other	-0.91	0.38	0.18	-0	-0.07	-
Total Common Equity	104.03	343.43	224.53	196.99	192.9	166.73
Shareholders' Equity	104.03	343.43	224.53	196.99	192.9	166.73
Total Liabilities & Equity	505.5	562.16	376.99	265.49	227.86	178.91

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	89.43	83.04	72.45	30.22	20.16	1.19
Net Cash (Debt)	220.18	334.23	218.92	197.23	196.87	170.62
Net Cash Growth	-31.05%	52.67%	11.00%	0.18%	15.38%	1.99%
Net Cash Per Share	5.02	8.00	5.82	6.71	8.00	8.30
Filing Date Shares Outstanding	49.31	42.56	38.38	34.22	26.73	20.71
Total Common Shares Outstanding	49.3	42.55	38.35	34.21	26.73	20.7
Working Capital	218.3	387.09	276.09	219.2	209.95	164.47
Book Value Per Share	2.11	8.07	5.85	5.76	7.22	8.06
Tangible Book Value	87.38	336.06	216.21	193.12	192.9	166.73
Tangible Book Value Per Share	1.77	7.90	5.64	5.64	7.22	8.06
Machinery	7.16	3.84	3.5	2.08	1.08	0.85
Leasehold Improvements	16.28	9.93	0.79	0.68	0.43	0.13

SEC Filings: 10-K · 10-Q